Apatinib tablet is a small-molecule targeted drug against VEGFR-2 that blocks downstream signal transduction and inhibits tyrosine kinase production through highly selective competition for ATP binding sites of intracellular receptor-2, thus inhibiting neoangiogenesis in tumour tissues and finally achieving the purpose of tumour treatment [8]. Here, KDR is linked to neoplasm.